Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
Sponsor: Eye & ENT Hospital of Fudan University
Summary
This is a multi-center, randomized controlled, prospective clinical study.
Official title: Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Multicenter Randomized Controlled Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
116
Start Date
2025-12-22
Completion Date
2029-12-30
Last Updated
2025-12-23
Healthy Volunteers
No
Conditions
Interventions
Finolizumab
200mg every 3 weeks (q3w) for 2 cycles.
Albumin-Bound Paclitaxel /nab-Paclitaxel
260mg/m², day 1, every 3 weeks (q3w) for 2 cycles.
Cisplatin
25mg/m², days 1-3, every 3 weeks (q3w) for 2 cycles.
Definitive radiotherapy
Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg/m², days 1-3, every 3 weeks)
Surgery with postoperative radiotherapy or chemoradiotherapy.
surgery with postoperative radiotherapy or chemoradiotherapy.
Locations (7)
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Shandong Provincial ENT Hospital
Jinan, Shandong, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Eye & ENT Hospital, Fudan University
Shanghai, China
Zhongshan Hospital of Fudan University
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China